New knowledge about treating multiple sclerosis

February 3, 2014

(Medical Xpress)—A study carried out at Victoria, and recently published online in the international scientific journal PLOS ONE, holds promise for patients suffering from secondary progressive MS, an advanced form of the disease, which causes nerve degeneration leading to impaired vision and coordination, and eventually, paralysis.

The study focused on understanding how a new MS drug, MIS416, developed by the New Zealand biotech company Innate Immunotherapeutics, is able to help with secondary progressive MS, a form of MS with few effective treatments.

The team of scientists includes Dr Anne La Flamme, an Associate Professor in Victoria's School of Biological Sciences and head of the MS Research Programme at the Malaghan Institute of Medical Research, PhD student Madeleine White, and Dr Gill Webster from Innate Immunotherapeutics.
"We know this drug works, but we are not sure why. This study has helped us understand the pathways that are driving the disease and how the medication alters the immune system, giving us a better idea of why MIS416 works as well as insight into how to treat patients and predict who will do better on this sort of medication," says Dr La Flamme.

Most people believe MS revolves around T cells, says Dr La Flamme, but the Victoria study reveals that targeting other cells in the central nervous system can significantly reduce advanced forms of MS.

Explore further: Cancer drug a possible treatment for multiple sclerosis

More information: White M, Webster G, O'Sullivan D, Stone S, La Flamme AC (2014) Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis. PLoS ONE 9(1): e87712. DOI: 10.1371/journal.pone.0087712

Related Stories

Cancer drug a possible treatment for multiple sclerosis

February 21, 2013

(Medical Xpress)—A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE. The discovery, ...

Patients curious about medical marijuana treatments

January 16, 2014

Ever since medical marijuana became legal in Illinois on Jan. 1, Loyola University Medical Center neurologist and multiple sclerosis specialist Dr. Matthew McCoyd has been inundated with questions from his patients.

Recommended for you

New insights on how cocaine changes the brain

November 25, 2015

The burst of energy and hyperactivity that comes with a cocaine high is a rather accurate reflection of what's going on in the brain of its users, finds a study published November 25 in Cell Reports. Through experiments conducted ...

Can physical exercise enhance long-term memory?

November 25, 2015

Exercise can enhance the development of new brain cells in the adult brain, a process called adult neurogenesis. These newborn brain cells play an important role in learning and memory. A new study has determined that mice ...

Umbilical cells help eye's neurons connect

November 24, 2015

Cells isolated from human umbilical cord tissue have been shown to produce molecules that help retinal neurons from the eyes of rats grow, connect and survive, according to Duke University researchers working with Janssen ...

Brain connections predict how well you can pay attention

November 24, 2015

During a 1959 television appearance, Jack Kerouac was asked how long it took him to write his novel On The Road. His response – three weeks – amazed the interviewer and ignited an enduring myth that the book was composed ...

No cable spaghetti in the brain

November 24, 2015

Our brain is a mysterious machine. Billions of nerve cells are connected such that they store information as efficiently as books are stored in a well-organized library. To this date, many details remain unclear, for instance ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.